Literature DB >> 19478397

Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins.

Tetsuya Kimura1, Xiao-Hong Wang, Constance Williams, Susan Zolla-Pazner, Miroslaw K Gorny.   

Abstract

A human anti-HIV monoclonal antibody (mAb), 2909, selected on the basis of its potent neutralizing activity against HIV-1SF162, recognizes a complex epitope V2/V3 present on intact virions but not on soluble gp120. To confirm the quaternary nature of the epitope, 2909 binding was tested against the pseudovirus SF162 wild type (WT) expressing trimers and/or an SF162 mutant expressing monomeric envelope proteins. The construction of the SF162 mutant was made by an alanine substitution of nine hydrophobic residues in the N-terminal heptad repeat region of gp41 molecules that failed to form trimers on the virus surface. Monoclonal Ab 2909 bound only to SF162 WT virions and transfected cells as determined by immunoprecipitation and flow cytometry, respectively, but showed no reactivity to the SF162 mutant expressing monomeric gp120. The data provide further evidence for the existence of a unique quaternary epitope V2/V3 on the surface of unliganded virus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19478397      PMCID: PMC3887469          DOI: 10.3233/HAB-2009-0200

Source DB:  PubMed          Journal:  Hum Antibodies        ISSN: 1093-2607


  25 in total

1.  Distribution and three-dimensional structure of AIDS virus envelope spikes.

Authors:  Ping Zhu; Jun Liu; Julian Bess; Elena Chertova; Jeffrey D Lifson; Henry Grisé; Gilad A Ofek; Kenneth A Taylor; Kenneth H Roux
Journal:  Nature       Date:  2006-05-24       Impact factor: 49.962

2.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

3.  Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.

Authors:  Miroslaw K Gorny; Leonidas Stamatatos; Barbara Volsky; Kathy Revesz; Constance Williams; Xiao-Hong Wang; Sandra Cohen; Robert Staudinger; Susan Zolla-Pazner
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.

Authors:  J He; S Choe; R Walker; P Di Marzio; D O Morgan; N R Landau
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys.

Authors:  B Etemad-Moghadam; G B Karlsson; M Halloran; Y Sun; D Schenten; M Fernandes; N L Letvin; J Sodroski
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation.

Authors:  J C Bandres; Q F Wang; J O'Leary; F Baleaux; A Amara; J A Hoxie; S Zolla-Pazner; M K Gorny
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.

Authors:  W J Honnen; C Krachmarov; S C Kayman; M K Gorny; S Zolla-Pazner; A Pinter
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

8.  Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins.

Authors:  A Gigler; S Dorsch; A Hemauer; C Williams; S Kim; N S Young; S Zolla-Pazner; H Wolf; M K Gorny; S Modrow
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

9.  Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.

Authors:  R I Connor; B K Chen; S Choe; N R Landau
Journal:  Virology       Date:  1995-02-01       Impact factor: 3.616

10.  Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ.

Authors:  Giulia Zanetti; John A G Briggs; Kay Grünewald; Quentin J Sattentau; Stephen D Fuller
Journal:  PLoS Pathog       Date:  2006-08       Impact factor: 6.823

View more
  13 in total

1.  Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1.

Authors:  Anita Changela; Xueling Wu; Yongping Yang; Baoshan Zhang; Jiang Zhu; Glenn A Nardone; Sijy O'Dell; Marie Pancera; Miroslaw K Gorny; Sanjay Phogat; James E Robinson; Leonidas Stamatatos; Susan Zolla-Pazner; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

2.  Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities.

Authors:  Chavdar Krachmarov; Zhong Lai; William J Honnen; Aidy Salomon; Miroslaw K Gorny; Susan Zolla-Pazner; James Robinson; Abraham Pinter
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

3.  Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding.

Authors:  Carlos G Moscoso; Yide Sun; Selina Poon; Li Xing; Elaine Kan; Loïc Martin; Dominik Green; Frank Lin; Anders G Vahlne; Susan Barnett; Indresh Srivastava; R Holland Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-28       Impact factor: 11.205

4.  P2X1 Selective Antagonists Block HIV-1 Infection through Inhibition of Envelope Conformation-Dependent Fusion.

Authors:  Alexandra Y Soare; Hagerah S Malik; Natasha D Durham; Tracey L Freeman; Raymond Alvarez; Foramben Patel; Namita Satija; Chitra Upadhyay; Catarina E Hioe; Benjamin K Chen; Talia H Swartz
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

Review 5.  Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.

Authors:  Susan Zolla-Pazner; Timothy Cardozo
Journal:  Nat Rev Immunol       Date:  2010-07       Impact factor: 53.106

Review 6.  Structure-based vaccine design in HIV: blind men and the elephant?

Authors:  Robert Pejchal; Ian A Wilson
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

7.  A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design.

Authors:  Yuxin Chen; Michael Vaine; Aaron Wallace; Dong Han; Shengqin Wan; Michael S Seaman; David Montefiori; Shixia Wang; Shan Lu
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

8.  Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject.

Authors:  Liuzhe Li; Xiao-Hong Wang; Sagarika Banerjee; Barbara Volsky; Constance Williams; Diana Virland; Arthur Nadas; Michael S Seaman; Xuemin Chen; Paul Spearman; Susan Zolla-Pazner; Miroslaw K Gorny
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

9.  Basic research in HIV vaccinology is hampered by reductionist thinking.

Authors:  Marc H V Van Regenmortel
Journal:  Front Immunol       Date:  2012-07-09       Impact factor: 7.561

10.  Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.

Authors:  Guomiao Shen; Chitra Upadhyay; Jing Zhang; Ruimin Pan; Susan Zolla-Pazner; Xiang-Peng Kong; Catarina E Hioe
Journal:  PLoS One       Date:  2015-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.